To Identify An Enzyme Or Isoenzyme Patents (Class 435/7.4)
  • Publication number: 20140323346
    Abstract: The present disclosure generally relates to protein binding agents, such as protein kinase binding agents of general Formula (I). The protein binding agents may be provided attached to a solid support and may be used, for example, to detect the presence of a broad range of proteins in a sample. Methods of synthesizing the protein binding agents, and kits comprising the protein binding agents, are also disclosed.
    Type: Application
    Filed: November 21, 2012
    Publication date: October 30, 2014
    Applicant: Garvan Institute of Medical Research
    Inventors: Roger John Daly, Ian Peter Holmes, Ian Street, Scott Raymond Walker
  • Publication number: 20140322725
    Abstract: The present invention provides compositions comprising chimeric polypeptides that bind to free ubiquitin proteins or free ubiquitin-like proteins with high affinity, as well as chimeric polypeptides that bind to both free and conjugated ubiquitin proteins or free and conjugated ubiquitin-like proteins, and methods of using the chimeric polypeptides to determine the amount of free or total ubiquitin or free or total ubiquitin-like proteins in various types of samples.
    Type: Application
    Filed: April 30, 2014
    Publication date: October 30, 2014
    Applicant: Colorado State University Research Foundation
    Inventors: Robert E. Cohen, Yun-Seok Choi
  • Publication number: 20140322726
    Abstract: It is an object of the present invention to provide a monoclonal antibody, which is suitable for the quantitative analysis of asparagine synthetase in a cell. The present invention provides a monoclonal antibody which specifically recognizes asparagine synthetase that is present in a cell.
    Type: Application
    Filed: October 3, 2012
    Publication date: October 30, 2014
    Inventors: Takao Hamakubo, Yasuhiro Mochizuki, Hiroko Iwanari, Osamu Arai, Toshiyuki Kitoh, Masahito Tsurusawa
  • Publication number: 20140323350
    Abstract: A lateral test flow arrangement for a test molecule is disclosed, comprising: a test strip for transporting an analyte away from a sampling region and towards an absorbing region, the test strip having therein and remote from the sampling region, a test region for functionalization with a molecule which binds to the test molecule or to a conjugate of the test molecule; a sensing test capacitor having electrodes extending across the test strip at least partially aligned with the test region and being physically isolated therefrom; a reference test capacitor having electrodes extending across the test strip and being physically isolated therefrom; and an electronic circuit configured to measure a time-dependant capacitance difference between the sensing test capacitor and the reference test capacitor.
    Type: Application
    Filed: December 6, 2012
    Publication date: October 30, 2014
    Applicant: NXP B.V.
    Inventors: Viet Nguyen, Franciscus Petrus Widdershoven, Roel Daamen
  • Publication number: 20140323324
    Abstract: The purpose of the present invention is to develop: a method for selectively separating a glycoprotein derived from the central nervous system from a body fluid or a central nervous system cell; and a method for searching for an index marker for central nervous system diseases, which utilizes the aforementioned method. A protein derived from the central nervous system, which occurs in a trace amount in a body fluid or a central nervous system cell, can be selectively enriched by a two-stage separation procedure comprising removing a glycoprotein having sialic acid at a non-reducing terminal thereof from the body fluid or the central nervous system cell and then separating a glycoprotein having N-acetylglucosamine at a non-reducing terminal thereof.
    Type: Application
    Filed: December 16, 2011
    Publication date: October 30, 2014
    Applicant: National Institute of Advanced Industrial Science and Technology
    Inventors: Hisashi Narimatsu, Jun Hirabayashi, Atsushi Kuno, Hideki Matsuzaki, Yuzuru Ikehara, Hiromi Ito, Yasuhiro Hashimoto, Keiro Shirotani, Satoshi Futakawa, Hajime Arai, Masakazu Miyajima, Kazuo Fujihara
  • Publication number: 20140322699
    Abstract: The invention as disclosed herein provides a method for purifying a non-antibody protein from solution, comprising a chromatography step wherein the solution is passed over an affinity construct containing an affinity ligand-coupled solid support, wherein the affinity construct is associated with a bioprocess unit operation, and isolating the non-antibody protein from solution.
    Type: Application
    Filed: July 8, 2014
    Publication date: October 30, 2014
    Applicant: Genzyme Corporation
    Inventors: Veena Warikoo, Kevin Brower
  • Patent number: 8871455
    Abstract: Methods and kits are provided for assessing radiation injury and exposure in a subject. The methods comprise measuring the levels of at least two (2) protein biomarkers from different biological pathways and correlating the levels with an assessment of radiation injury and exposure. Additional use of peripheral blood cell counts and serum enzyme biomarkers, evaluated in the early time frame after a suspected radiation exposure, and use of integrated multiple parameter triage tools to enhance radiation exposure discrimination and assessment are also provided. The information obtained from such methods can be used by a clinician to accurately assess the extent of radiation injury/exposure in the subject, and thus will provide a valuable tool for determining treatment protocols on a subject by subject basis.
    Type: Grant
    Filed: June 12, 2007
    Date of Patent: October 28, 2014
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: William Blakely, Natalia Ossetrova, Marcy Grace, Alexandra Miller, Jean Mulimbi Muderhwa, Glen Manglapus
  • Publication number: 20140315215
    Abstract: There is provided a single-chain fusion protein comprising: (i) a thermostable kinase and (ii) a single-domain antibody or single-domain antibody fragment. There is also provided a method of preparing a single-domain antibody or single-domain antibody fragment, the method comprising: (i) expressing the single-domain antibody or antibody fragment as a single-chain fusion protein with a thermostable kinase, in a host cell such as E. coli; and (ii) purifying the fusion protein from the cytoplasm of the host cell.
    Type: Application
    Filed: September 14, 2012
    Publication date: October 23, 2014
    Applicant: The Secretary of State for Health
    Inventors: John Mark Sutton, Philip James Alister Skipper
  • Publication number: 20140315752
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Stanniocalcin-1, Antithrombin-III, Toll-like receptor 2, Triiodothyronine (T3), Thyroxine (T4), Extracellular matrix protein 1, Coagulation factor XIII A chain, Coagulation factor XIII B chain, Interleukin-17F, Interleukin-22, Vitronectin, Progesterone, Estradiol, Growth/differentiation factor 15, and Proprotein convertase subtilisin/kexin type 9 as diagnostic and prognostic biomarkers in renal injuries.
    Type: Application
    Filed: November 20, 2012
    Publication date: October 23, 2014
    Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
  • Publication number: 20140315929
    Abstract: This invention concerns a method for selecting an inhibitor of a cancer-implicated pathway or of a component of a cancer-implicated pathway for coadministration, with an inhibitor of HSP90, to a subject suffering from a cancer which comprises the following steps: (a) contacting a sample containing cancer cells from a subject with an inhibitor of HSP90 or an analog, homolog or derivative of an inhibitor of HSP90 under conditions such that one or more cancer pathway components present in the sample bind to the HSP90 inhibitor or the analog, homolog or derivative of the HSP90 inhibitor; (b) detecting pathway components bound to the HSP90 inhibitor or to the analog, homolog or derivative of the HSP90 inhibitor; (c) analyzing the pathway components detected in step (b) so as to identify a pathway which includes the components detected in step (b) and additional components of such pathway; and (d) selecting an inhibitor of the pathway or of a pathway component identified in step (c).
    Type: Application
    Filed: April 27, 2012
    Publication date: October 23, 2014
    Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventor: Gabriela Chiosis
  • Publication number: 20140315217
    Abstract: A method for assaying activity of the enzyme spermidine/spermine N1-acetyltransferase (SSAT) uses SSAT substrates by detecting their acetylated forms. SSAT substrates may include rimantadine and tocainide wherein their metabolism occurs in part by the action of the inducible enzyme SSAT to produce the acetylated metabolites N-acetylrimantadine and N-acetyltocainide respectively. SSAT activity may be correlated to pathologic conditions.
    Type: Application
    Filed: November 16, 2012
    Publication date: October 23, 2014
    Applicant: BioMark Technologies Inc.
    Inventors: Brian Cheng, Rashid Bux, Daniel Sitar
  • Publication number: 20140315214
    Abstract: In some aspects, the invention provides methods of identifying, detecting, and/or measuring protein-protein interactions. In some aspects, the invention provides methods of identifying and/or characterizing modulators of protein-protein interactions. In some aspects, the invention provides methods of identifying and/or characterizing modulators of protein activity, wherein the methods are based at least in part on measuring interaction between a chaperone and client protein. In some aspects, the invention provides methods for identifying and/or characterizing compounds and/or for assessing compound specificity, wherein the methods are based at least in part on measuring interaction between a chaperone and client protein. In some embodiments, a client protein is a kinase. In some embodiments, a compound is a kinase inhibitor. In some aspects, the invention provides methods of profiling kinase inhibitor specificity.
    Type: Application
    Filed: May 9, 2012
    Publication date: October 23, 2014
    Applicant: Whitehead Institute foe Biomedical Research
    Inventors: Mikko Taipale, Susan Lindquist
  • Publication number: 20140315216
    Abstract: An immunoassay test slide for use in a dry chemistry analytical instrument includes a slide housing or case formed from two matable sections—a slide cover piece and a slide bottom piece. The slide housing defines an interior cavity in which is situated a sheet-like porous carrier matrix. The slide cover piece has an opening formed through the thickness thereof to expose a central portion of the fluid flow matrix so that a precise volume of fluid sample of blood, serum or the like, preferably pre-mixed with a conjugate reagent, and precise volumes of a wash reagent and a substrate (detector reagent), may be deposited on the matrix through the cover opening by a metering device of the analytical instrument. The bottom piece of the immunoassay test slide is transparent, and the slide is moved by a transport mechanism of the analytical instrument over a reflectometer or a fluorometer for performing reflectance or fluorescence measurements.
    Type: Application
    Filed: January 7, 2013
    Publication date: October 23, 2014
    Inventors: Eugene Chan, Keith Nassif
  • Patent number: 8865420
    Abstract: The present invention provides an approach for the simultaneous determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of potentiators of cellular activation allows for characterization of such pathways and cell populations.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: October 21, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Omar D. Perez, Garry P. Nolan, Jonathan M. Irish
  • Publication number: 20140309135
    Abstract: A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the ? subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the ? subunit of a trimeric GTP-binding protein, as the active ingredient, etc.
    Type: Application
    Filed: April 25, 2014
    Publication date: October 16, 2014
    Applicant: AJINOMOTO CO., INC.
    Inventors: Naoyuki FUKUCHI, Satoru Okamoto, Wataru Miyanaga, Sen Takeshita, Masaru Takayanagi, Yumiko Fukuda, Takao Ikenoue, Naoyuki Yamada, Naoko Arashida
  • Publication number: 20140309171
    Abstract: The invention relates to the use of phosphorylated Acetyl-CoA carboxylase (ACC) in platelets from a subject as a biomarker for blood coagulation, preferably blood coagulation in the subject, preferably encompassing activation of the coagulation cascade as well as platelet activation, preferably thrombin-induced platelet activation. The invention encompasses uses and methods for the diagnosis or the monitoring of blood coagulation in the subject. The invention further relates to uses and methods for screening for anti-coagulants or pro-coagulants.
    Type: Application
    Filed: November 21, 2012
    Publication date: October 16, 2014
    Inventors: Sandrine Horman, Christophe Beauloye, Marie-Blanche Onselaer, Luc Bertrand, Jean-Louis Vanoverschelde
  • Publication number: 20140309141
    Abstract: Methods and compositions for detection of the modulators of proteolytic enzymes, particularly cysteine proteases, are disclosed.
    Type: Application
    Filed: September 21, 2012
    Publication date: October 16, 2014
    Inventors: Craig Leach, James Strickler, Michael Eddins
  • Publication number: 20140308679
    Abstract: The invention relates to fluorometry, and in particular to methods and apparatus for time-delayed detection of fluorescence in a sample, for example for use in a clinical setting. Exemplary embodiments disclosed relate to a fluorometer (100) comprising a light source (101), a light detector (102), a sample holder (103) disposed between the light source and light detector, a motor (104); and a light transmission modulator (105) disposed around the sample holder and comprising a pair of plates (106, 107) attached to the motor for rotation about a common axis (108), the pair of plates arranged to allow transmission from the source to the sample in a first rotated position, to allow transmission from the sample to the detector in a second rotated position and to block direct light transmission between the source and detector in both first and second rotated positions.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 16, 2014
    Inventors: Edward John Thompson, Ilan Tal
  • Publication number: 20140308242
    Abstract: The invention relates to biomarkers measurable in a human subject that have prognostic value with respect to efficacy of therapeutic treatments for Hepatitis C viral infection. The markers also are believed to have value for diagnosis liver health/liver damage.
    Type: Application
    Filed: October 21, 2011
    Publication date: October 16, 2014
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Mark Andrew Fleming, Brain J. Hare, Daniel Chelsky, Rene Allard, Eustache Paramithiotis
  • Publication number: 20140308680
    Abstract: The present invention relates to a method for simultaneous detection of the coagulation activity of a blood sample and of the presence and/or amount of at least one target molecule within said blood sample, comprising the steps of: i) introducing a blood sample into a sample container comprising magnetic particles and a sensor surface, wherein said magnetic particles are functionalized with a first binding molecule, wherein said first binding molecule is attached to said magnetic particles, wherein the first binding molecule is capable of specifically binding to the at least one target molecule within said blood sample, and wherein a second binding molecule is attached to a sensor surface at the bottom of said sample container, and wherein said second binding molecule of the sensor surface is capable of specifically binding to the at least one target molecule within said blood sample; ii) measuring the presence and/or amount of said target molecule by detecting the number of magnetic particles bound to said s
    Type: Application
    Filed: October 3, 2012
    Publication date: October 16, 2014
    Inventor: Ron Martinus Laurentius Van Lieshout
  • Publication number: 20140309263
    Abstract: The present invention relates to methods of diagnosing a kidney disorder in a patient, as well as methods of monitoring the progression of a kidney disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.
    Type: Application
    Filed: January 31, 2014
    Publication date: October 16, 2014
    Applicant: MESO SCALE TECHNOLOGIES, LLC
    Inventors: Simone Barbero, Eli N. Glezer, Anu Mathew, Mingyue Wang
  • Patent number: 8859223
    Abstract: Molecular probes are provided for use in fluorescence microscopy procedures for monitoring beta-secretase enzyme (BACE) activity in living cells and organisms. The probes may be useful for monitoring Alzheimer's Disease-associated BACE in living cells. By fluorescing when hydrolyzed by BACE, the probes can allow for real-time spatial and temporal assessment of enzymatic activity without the need for mutated cell lines or antibodies. The molecular probes may also be used to screen libraries of potential BACE inhibitors or evaluate how external stimuli affect BACE activity.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 14, 2014
    Assignee: Duke University
    Inventors: Katherine J. Franz, Drew Folk
  • Publication number: 20140303165
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: June 4, 2014
    Publication date: October 9, 2014
    Inventors: Juswinder Singh, Shomir Ghosh, Arthur F. Kluge, Russell C. Petter, Richland W. Tester
  • Publication number: 20140303191
    Abstract: Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor.
    Type: Application
    Filed: October 19, 2012
    Publication date: October 9, 2014
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Publication number: 20140303018
    Abstract: Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (NAFLD) are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatohepatitis (NASH) are also provided.
    Type: Application
    Filed: March 10, 2014
    Publication date: October 9, 2014
    Applicant: SomaLogic, Inc.
    Inventors: Malti Nikrad, Stuart G. Field, Stephen Alaric Williams
  • Publication number: 20140302524
    Abstract: The present disclosure provides lysyl oxidase-like-2 (LOXL2) polypeptide binding agents, including, for example, antibodies that specifically bind a LOXL2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided.
    Type: Application
    Filed: February 4, 2014
    Publication date: October 9, 2014
    Applicant: GILEAD BIOLOGICS, INC.
    Inventors: Scott Alan MCCAULEY, Hector RODRIGUEZ, Carlos Aurelio GARCIA, Victoria SMITH
  • Publication number: 20140302047
    Abstract: This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Application
    Filed: June 19, 2014
    Publication date: October 9, 2014
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Publication number: 20140302526
    Abstract: Detection of ZAP-70 expression provides important information about disease progression and overall survival in patients with chronic lymphocytic leukemia (CLL). The invention provides methods for diagnosing CLL in a subject, as well as methods for clearly distinguishing CLL patients with aggressive form of the disease. A consistent number of B cells from patient blood is isolated and lysed to release all of the intracellular ZAP-70 protein. The released ZAP-70 protein is subsequently extracted by immunomagnetic separation followed by detection with fluorescence immunosandwich assay. The ZAP-70 fluorescence signal is measured with Signalyte™-II spectrofluorometer. The VeriZAP™ assay is a simple, reliable, and reproducible method for quantitative detection of ZAP-70 in patient leukemic cells, and can be used as a prognostic test to distinguish indolent versus aggressive CLL patients.
    Type: Application
    Filed: November 2, 2012
    Publication date: October 9, 2014
    Inventors: Cha-Mei Tang, Peixuan Zhu
  • Publication number: 20140301945
    Abstract: Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: December 19, 2011
    Publication date: October 9, 2014
    Applicants: UNIVERSITY OF ZURICH, NEURIMMUNE HOLDING AG
    Inventors: Fabio Montrasio, Maria Grazia Barenco Montrasio, Jan Grimm, Roger Nitsch, Christoph Hock, Tobias Welt, Jordan McAfoose, Marcel Maier
  • Publication number: 20140302499
    Abstract: Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors.
    Type: Application
    Filed: June 20, 2014
    Publication date: October 9, 2014
    Inventors: Gera NEUFELD, Gal AKIRI, Zahava VADASZ, Stela GENGRINOVITCH
  • Publication number: 20140302998
    Abstract: The present application provides stable peptide-based Akt capture agents and the use thereof as detection, diagnosis, and treatment agents. The application further provides novel methods of developing stable peptide-based capture agents, including Akt capture agents, using iterative on-bead in situ click chemistry.
    Type: Application
    Filed: July 11, 2012
    Publication date: October 9, 2014
    Inventors: James R. Heath, Arundhati Nag, Samir Das, Kaycie M. Deyle, Steven Wesley Millward, Paul Edward Kearney
  • Publication number: 20140302525
    Abstract: Provided herein are methods of detecting binding of an SENP1 polypeptide to a compound and methods for screening for inhibitors of SENP1. Further provided are aqueous compositions comprising SENP1 polypeptides and NMR apparatuses comprising the compositions for NMR analysis.
    Type: Application
    Filed: April 7, 2014
    Publication date: October 9, 2014
    Applicant: City of Hope
    Inventor: Yuan Chen
  • Patent number: 8852869
    Abstract: The present invention relates to a method of in vitro determining functional deficiencies in the lectin pathway of the complement system, the method comprises the steps of (a) diluting a mammalian sample of body fluid with a diluent comprising one or more inhibitors of the activation of the classical and the alternative pathways of the complement system; (b) activating the lectin pathway of the complement system in the sample obtained from (a); and (c) determining in the sample obtained from (b) the activation of one or more of the complement factors C3, C4, or one or more of the components of the C5-C9 complex. The invention furthermore relates to kits for use in connection with the above-mentioned method, the first kit comprises i) a first component comprising a carrier, one or more inhibitors of the classical and the alternative complement pathways and a diluent; and ii) a second component comprising one or more substances for activation of the lectin complement pathway and optionally an inert carrier.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: October 7, 2014
    Assignee: Immunobond ApS
    Inventors: Yaseelan Palarasah, Mikkel Ole Skjødt, Lars Vitved, Claus Koch
  • Publication number: 20140296172
    Abstract: A method of screening compounds or molecules comprising the steps of: translating a sequence encoding the amino acid sequence comprising SEQ ID No. 29 in a translation system in the presence of a test compound or molecule; and analysing the translation product(s) for the presence of one or more of (a) a peptide comprising the amino acids Pro-Gly at the C terminus and a peptide comprising the amino acid Pro at the N terminus: or (b) a peptide comprising the amino acid sequence of SEQ ID No. 29.
    Type: Application
    Filed: September 23, 2013
    Publication date: October 2, 2014
    Applicants: UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWS, UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK
    Inventors: John Fuller Atkins, Martin Ryan, Gary Loughran
  • Publication number: 20140295457
    Abstract: The present invention refers to the gene cluster and genes comprised by the gene cluster which are involved in the biosynthesis of griselimycin and methylgriselimycin and to the use of the gene cluster, genes comprised thereby and proteins encoded thereby for the production of antibiotic agents.
    Type: Application
    Filed: October 11, 2012
    Publication date: October 2, 2014
    Inventors: Mark Broenstrup, Claudia Koenig, Luigi Toti, Joachim Wink, Wulf Leuschner, Johann Gassenhuber, Rolf Müller, Silke Wenzel, Tina Binz, Carsten Volz
  • Publication number: 20140298494
    Abstract: Some aspects of this invention provide a non-human animal model of autism. Some aspects of this invention provide a non-human animal model for diseases or disorders associated with an overexpression or a copy number variance of a Ube3a gene. Transgenic mammals and transgenic mammalian cells comprising an exogenous copy or exogenous copies of a ube3a protein-encoding nucleic acid sequence are also provided. Some aspects of this invention further provide methods for using the animal models, cells, and transgenic animals for identifying agents or interventions that can alleviate a pathogenic characteristic observed in the animal model, cell, or transgenic animal.
    Type: Application
    Filed: July 23, 2012
    Publication date: October 2, 2014
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Matthew P. Anderson
  • Publication number: 20140295455
    Abstract: The present invention provides an antibody capable of specifically recognizing and detecting the highly specific cancer marker with respect to the epithelial ovarian cancer, or a fragment of the antibody. The present invention provides an anti-?1,3-N-acetylglucosaminyltransferase 3 antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase ?1,3-N-acetylglucosaminyltransferase 3 as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1.
    Type: Application
    Filed: July 26, 2012
    Publication date: October 2, 2014
    Applicant: National Institute of Advanced Industrial Science and Technology
    Inventors: Maki Sogabe, Tomomi Kubota, Akira Togayachi, Yuzuru Ikehara, Hisashi Narimatsu, Hiromichi Sawaki, Hayao Nakanishi, Toru Nakanishi
  • Publication number: 20140294846
    Abstract: The present invention relates to ADAMTS-1 and uses thereof. The present invention also relates to fragments of ADAMTS-1 and methods of inhibiting cell growth and metastasis. The present invention also provide methods of identifying inhibitors and activators relating to the function of ADAMTS-1.
    Type: Application
    Filed: February 18, 2014
    Publication date: October 2, 2014
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: Qin Yu
  • Publication number: 20140294870
    Abstract: Compounds that bind to phosphatidylinositol-4-kinase III? (PI4KIII?) and inhibit the binding of PI4KIII? to its substrate and/or inhibit PI4KIII? activity may be used in the treatment and/or prevention of an autoimmune or inflammatory disorder, or organ or cell transplant rejection. A new assay for identifying compounds for use in treating and/or preventing those pathological conditions, which comprises measuring the inhibition of PI4KIII? activity, is also disclosed.
    Type: Application
    Filed: September 7, 2012
    Publication date: October 2, 2014
    Applicant: KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D
    Inventors: Jean Herman, Thierry Louat, Qiuya Huang, Bart Vanderhoydonck, Mark Waer, Piet Herdewijn
  • Publication number: 20140295456
    Abstract: Disclosed herein is a method of identifying a tumor biomarker. In one example, a tumor biomarker is identified by obtaining a peripheral biological fluid sample from a subject with a tumor as well as a tumor sample and an adjacent non-tumor sample from such subject. A protein expression profile is detected in the peripheral biological fluid sample, tumor sample and adjacent non-tumor sample. The protein expression profiles of the peripheral biological fluid sample, tumor sample and adjacent non-tumor sample are then compared, wherein an increase in expression of a specific protein in the tumor sample and peripheral biological fluid sample but not in the adjacent non-tumor sample indicates that the specific protein is a biomarker of the tumor. Also disclosed herein is a gene profiling signature that can be used to diagnosis a subject with renal cell carcinoma (RCC) or to identify agents with therapeutic potential to treat RCC. Thus, methods of diagnosing a subject with RCC are disclosed.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 2, 2014
    Inventors: Josip Blonder, Bih-Rong Wei, Donald J. Johann, JR., Timothy D. Veenstra
  • Publication number: 20140294854
    Abstract: The present invention provides compositions and methods for treating obesity in a subject by administering an inhibitor of UBE2L6 or an activator of adipocyte triglyceride lipase to the subject.
    Type: Application
    Filed: March 8, 2012
    Publication date: October 2, 2014
    Applicant: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Streamson Coo Chua, Shun-Mei Liu, Genevieve Marcelin
  • Publication number: 20140287956
    Abstract: Methods for diagnosing cancer and monitoring treatment efficacy based on detecting the presence of increased levels of expression of satellite correlated genes.
    Type: Application
    Filed: October 24, 2012
    Publication date: September 25, 2014
    Inventors: David Tsai Ting, Shyamala Maheswaran, Daniel A. Haber
  • Publication number: 20140288045
    Abstract: Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 25, 2014
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Jun Feng, Tao Wu
  • Publication number: 20140288162
    Abstract: Methods and compositions are provided for treating human synovial sarcoma (SS). Also provided are screens to identify therapeutics for the treatment of synovial sarcoma. These methods, compositions, and screens are based on the discovery that promoting the assembly of wild type BAF (also called mSWI/SNF) complexes in SS cells by increasing levels of wild type SS18 and/or decreasing levels of SS18-SSX fusion protein leads to the cessation of proliferation of malignant cells in synovial sarcoma.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 25, 2014
    Inventors: Cigall Kadoch, Gerald R. Crabtree
  • Publication number: 20140288007
    Abstract: The disclosure relates to compounds, peptides or peptidomimetics that inhibit, reduce or prevent protease activity and the use of these compounds, peptides or peptidomimetics to treat or prevent a condition. In particular the condition may be periodontal disease. The protease activity may be activity of a gingipain. The compounds, peptides or peptidomimetics of the invention may also be used in assays for the identification of protease inhibitors.
    Type: Application
    Filed: November 2, 2012
    Publication date: September 25, 2014
    Applicant: Oral Health Australia Pty. Ltd.
    Inventors: Stuart Geoffrey Dashper, Eric Charles Reynolds, Noorjahan Laila Huq, Elena Chiew Yeen Toh
  • Publication number: 20140287433
    Abstract: This invention relates to a method of determining presence, amount and/or activity of a clostridial neurotoxin in a sample, the method comprising or consisting of the following steps: (a) bringing said sample into contact with a liposome, said liposome comprising (aa) at least one receptor on its outer surface, said receptor being capable of binding said neurotoxin and comprising or consisting of (i) a glycolipid and (ii) a peptide or protein; and (ab) a substrate in its interior, said substrate (i) being cleavable by the peptidase comprised in said neurotoxin and (ii) generating a detectable signal upon cleavage, said detectable signal preferably being generated by (1) the donor of a FRET pair, said donor exhibiting increased fluorescence upon cleavage by said peptidase, (2) a luminescent compound formed upon said cleavage, or (3) an enzyme formed upon said cleavage; and (b) determining whether an increase in signal occurs as compared to the absence of said sample, wherein such increase is indicative of the
    Type: Application
    Filed: July 18, 2012
    Publication date: September 25, 2014
    Applicants: ETH ZÜRICH, VERTEIDIGUNG, BEVÖLKERUNGSSCHUTZ UND SPORT, TOXOGEN GMBH, MIPROLAB GMBH
    Inventors: Oliver Weingart, Marc Avondet, Martin Loessner, Andreas Rummel, Frank Gessler
  • Publication number: 20140286937
    Abstract: We provide an antibody capable of binding to an intracellular PRL-I or PRL-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-PRL antibodies may be capable of binding to intracellular PRL-I or PRL-3. They may be suitable for use as therapies against cancer or metastasis thereof, or in clinical diagnosis to identify PRL-3 or PRL-I positive patients.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 25, 2014
    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventor: Qi Zeng
  • Publication number: 20140288008
    Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 25, 2014
    Applicants: Daiichi Sankyo Company, Limited, Pieris AG
    Inventors: GABRIELE MATSCHINER, CHRISTINE ROTHE, ANDREAS HOHLBAUM, ANDREA ALLERSDORFER, RACHIDA SIHAM BEL AIBA, MARLON HINNER, ALEXANDER WIEDENMANN, SHINJI YAMAGUCHI, TAKAHIDE ABURATANI, RYUJI HASHIMOTO, TOHRU TAKAHASHI, CHIKAKO NAGASAKI, FUTOSHI NARA, TOMOHIRO NISHIZAWA
  • Publication number: 20140286954
    Abstract: Disclosed are mammalian tau proteases, as well as proteolytically-active fragments, variants, and mutants thereof. Also disclosed are polynucleotides and recombinant expression vectors that encode these polypeptides, as well as methods for producing such proteins in selected recombinant host cells, and for using the compositions in a variety of diagnostic and analytical assays.
    Type: Application
    Filed: May 18, 2012
    Publication date: September 25, 2014
    Applicant: Oligomerix, Inc
    Inventors: James G. Moe, Eliot Davidowitz, Patricia Lopez
  • Publication number: 20140287419
    Abstract: Compositions and methods comprising polynucleotides and polypeptides having dicamba decarboxylase activity are provided. Further provided are nucleic acid constructs, host cells, plants, plant cells, explants, seeds and grain having the dicamba decarboxylase sequences. Various methods of employing the dicamba decarboxylase sequences are provided. Such methods include, for example, methods for decarboxylating an auxin-analog, method for producing an auxin-analog tolerant plant, plant cell, explant or seed and methods of controlling weeds in a field containing a crop employing the plants and/or seeds disclosed herein. Methods are also provided to identify additional dicamba decarboxylase variants.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 25, 2014
    Inventors: Eric Althoff, Yih-En Andrew Ban, Linda A. Castle, Daniela Grabs, Jian Lu, Phillip A. Patten, Yumin Tao, Alexandre Zanghellini